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Kajian tentang choline kinase a (CK-a) pada pesakit jantung 
iskemik dan sukarelawan sihat 
Abstrak 
Penyakit jantung iskemik dijangka akan menjadi penyebab kematian utama 
sedunia pada tahun 2030. Penyakit yang membawa maut ini tidak menunjukkan 
tanda-tanda pada peringkat awal. Maka, pencegahan dan pengesanan awal 
melalui pengenalan penanda kardiak adalah cara terbaik untuk mengatasinya. 
Choline kinase a (CK-a) telah dikaji untuk mengesan kemungkinan protein ini 
sebagai bakal penanda kardiak. Tujuan kajian ini ialah untuk mengkaji perbezaan 
tarat CK-a pada darah di antara pesakit jantung iskemik dengan sukarelawan. 
Sam pel darah daripada sepuluh pesakit jantung iskemik dan 10 sukarelawan sihat 
telah dianalisis dengan menggunakan tindakbalas rantai polimerase (RT -PCR) 
untuk menguji kandungan mRNA bagi CK-a. Western blot telah dijalankan untuk 
mengesan kehadiran protein CK-a dalam darah. Sejurus itu, ujian ELISA juga telah 
dijalankan untuk menguji kepekatannya di dalam sampel darah. Protein C-reaktif 
(CRP) digunakan sebagai penunjuk standard untuk membezakan pesakit jantung 
iskemik dengan sukarelawan sihat. Analisis statistik bagi ujian parametrik 
dijalankan dengan Ujian t manakala ujian tidak parametrik dianalisis dengan ujian 
Mann-Whitney. Ujian statistik menunjukkan CRP mempunyai perbezaan yang 
ketara pada peringkat mRNA dan juga pada peringkat protein antara pesakit 
jantung iskemik dan sukarelawan sihat (Ujian t, p<0.001; ujian Mann-Whitney, 
p=0.009). Perbezaan signifikan antara peringkat mRNA bagi CK-a2 telah dikesan 
xi 
dengan penurunan signifikan pada kumpulan pesakit (Ujian t, p=0.032). Namun, 
peringkat mRNA bagi total CK-a tidak menunjukkan perbezaan signifikan dalam 
perbandingan pada pesakit dengan sukarelawan (Mann-Whitney, p=0.705). 
Sementara itu, kandungan protein CK-a telah menunjukkan perbezaan yang 
signifikan antara kedua-dua kumpulan dengan paras yang lebih rendah dicatatkan 
pada pesakit (Mann-Whitney, p=0.014). Walaupun kajian ini masih pada peringkat 
awal, keputusan kajian ini telah menunjukkan bahawa CK-a berpotensi sebagai 
salah satu penanda kardiak. 
xii 
A study of human choline kinase a (hCK-a) in patients with 
ischemic heart disease (IHD) and healthy volunteers 
Abstract 
Ischemic heart disease (IHD) is predicted to become the dominant cause of 
mortality worldwide by 2030. As a silent yet eventually fatal disease, prevention 
and early detection through discovery of cardiac biomarker are the best resolution 
for IHD. Human choline kinase a (hCK-a) was investigated for its possibility as a 
cardiac biomarker in this study. The aim of this study is to investigate the 
differences in the protein level and mRNA expression of hCK-a between IHD 
patients and healthy controls. Blood samples from 10 IHD patients and 10 healthy 
volunteers were analyzed for mRNA expression using RT-PCR. Western blot was 
performed as a checkpoint for detection of hCK-a protein in blood. Subsequently, 
ELISA test was conducted to measure the protein concentration of hCK-a protein. 
C-reactive protein (CRP) was used as a standard reference in this study to provide 
a parameter to distinguish between both study groups. Statistical analysis was 
performed to investigate the relationship between hCK-a with IHD. Parametric test 
was performed using independent t-test meanwhile non-parametric test was 
performed using Mann-Whitney test. As anticipated, CRP was found to be 
significant higher in expression both in mRNA level and protein level (Independent 
t-test, p<0.001; Mann-Whitney test, p= 0.019). In this study, a significant lower 
level of hCK-a2 mRNA expression in IHD patients was revealed (Independent t-
test, p=0.032). However, total hCK-a mRNA expression was found to have no 
xiii 
significant different between IHD patients and healthy volunteers (Mann-Whitney 
test, p=0.705). Protein expression level of hCK-a was found to be significantly 
lower in lHD patients as compared to healthy volunteers (Mann-Whitney test, 
p=0.014). Albeit preliminary, this study found that there may be a profound 
relationship between hCK-a and IHD. 
xiv 
1.0 Introduction 
Ischemic heart disease (IHD) is an. intractable disease that will soon become an 
eminent health problem worldwide. According to World Health Statistics 2008, 
deaths from cardiovascular diseases (IHD and cerebrovascular disease) will rise 
from 17.1 million in 2004 to 23.4 million in 2030 in a projected 67 million deaths 
due to all causes including communicable, noncommunicable and injury (WHO, 
2008). Among the 20 leading causes of deaths globally between 2002 and 2030, 
ischemic heart disease (IHD) has emerged as the top on the rank order of deaths, 
followed by cerebrovascular disease (stroke), HIV/AIDS and chronic obstructive 
pulmonary disease (COPD) (Fig 1.1 ). 
Regardless of the gender and socioeconomic status, the amount of worlds 
populations that will succumb to IHD is predicted to be the highest among the 
death of all causes by the year of 2030 (Mathers and Loncar, 2006). This 
apprehensive projection is supported by the ongoing increase in the prevalence of 
cardiovascular diseases worldwide. To present this scenario, cardiovascular 
diseases had claimed an estimate of 30°/o of all deaths or about 17.5 million people 
in the total 58 million deaths in the world in 2005 (WHO, 2005). 
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LEADING CAUSES OF DEATH, 2004 AND 2030 COMPARED 
2004 2030 
Disease or Injury Deaths Rank Rank Deaths Disease or Injury 
(%) (%) 
lschaemic hoart dlsoaso 12.2 1 1 14.2 lschacmJc hoort disoaso 
Cerebrovascular disoase 9.7 2 2 12.1 Cerebrovascular disoaso 
Lower respiratory infections 7.0 3 
~ 
3 8.6 Chronic obstrudivo pulmonary disease 
Cluonlc obstructive pulmonary disoaso 5.1 4 4 3.8 Lower rospiratory infoclbns 
Diarrhoeal diseases 3.6 5 5 3.6 Road traffiC accidents 
HIV/AIDS 3.5 6 6 3.4 Trnchca, bronchus, lung cancers 
TuberculosiS 2.5 7 7 3.3 Oiabotos mcl6tus 
Trachea, bronchus, lung cancers 2.3 8 8 2.1 Hypertensive heart diseaso 
Road traffic accidents 2.2 9 9 1.9 Stomach cancer 
Prematurity and 10\v birth weight 2.0 10 10 1.8 HIV/AIDS 
Neonalallnfcctbns and othe,.. 1.9 11 11 1.6 Nephritis and nephrosis 
Diabetes mellitus 1.9 12 12 1.5 S&lf-inflided injuries 
MaJaria 1.7 13 13 1.4 Uvorcancor 
Hypertensive hoart disoaso 1.7 14 14 1.4 Colon and rectum cancers 
Birth asphyxia and birth trauma 1.5 15 15 1.3 Oesophagus cancer 
Self-tnfllded injuries 1.4 16 16 1.2 Violcnoo 
Stomach cancer 1.4 17 17 1.2 Alzhaimor and other domontias 
Cinhosis of tho livot 1.3 18 18 1.2 Cirrhosis of tho liver 
Nephritis and nephrosis 1.3 19 19 1.1 Bro ast cnnoor 
Colon and rectum canoers 1.1 20 20 1.0 Tuberculosis 
Violonco 1.0 22 21 1.0 Neonatal infections and otoor• 
Broast cancer 0.9 23 22 0.9 Prematurity and low birth weight 
Oesophagus cancor 0.9 24 23 0.9 Diarrhoeal disoosos 
Alzheimer and other domentias 0.8 25 29 0.7 Birth asphyxia and birth trauma 
41 0.4 Malaria 
• C~e:s s6\l!lte neonatal infactions ard otw, non!ntaeiious causes arising In the perinatal penod. 
Figure 1.1. Projection on leading causes of death in 2030. Adopted from WHO, 2008. 
In Malaysia, cardiovascular diseases remain the predominantly leading cause of 
death by a non-communicable disease from the 1970s and have remained so since 
except in 1980 (Khoo et a/., 1991 ). According to a Ministry of Health (MOH) 
Hospitals' survey in 2006, 6,372 of lives were deprived by heart diseases and 
diseases of pulmonary circulation (MOH8 , 2006). Cardiovascular and circulatory 
diseases are also the most common reasons for acute medical hospital admissions 
in our country. IHD is the commonest cause of cardiovascular mortality and is still 
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remains one of the major health problems. Nationally IHD probably accounts for 
20-30o/o of all-cause mortality annually (MOHb, 2006). 
The true incidence of IHD and IHD-related deaths in Malaysia is unknown. All the 
data presented thus far relates only to the 122 MOH hospitals. Data on IHD cases 
and deaths at the 7 University and other non-MOH Government hospitals, and 211 
private hospitals is unavailable although it is suspected the number may be double 
the figures from MOH hospitals only (MOHb, 2006). 
With the presented illustrious statistic on IHD worldwide and in our country, this 
devastating health problem is striking the alarm of our concern. Thus, there is an 
urgent need to find ways to resolve the crisis of IHD as it is becoming a serious 
health issue in the foreseeable future. Emergency attention needs to be focused on 
the prevention and early detection of IHD besides superior clinical decision making, 
disease management and therapeutic applications to safe life from being 
threatened by IHD. 
The success of this challenge is contingent on knowledge and complete 
understanding of the underlying mechanisms that lead to IHD. IHD or myocardial 
ischemia occurred due to an imbalance between cardiac blood supply (perfusion) 
and myocardial oxygen demand. Reduction in coronary blood flow caused by 
obstructive atherosclerotic disease is the main cause of myocardial ischemia 
3 
despite increased demand (e.g., increased heart rate or hypertension), or 
diminished oxygen-carrying capacity (e.g., anemia, carbon monoxide poisoning) 
can also contribute to myocardial ischemia (Kumar eta/., 2007). 
As a direct consequence of insufficient blood supply to the heart, the IHD manifests 
clinically in the basic clinical syndromes such as angina pectoris, acute myocardial 
infarction, chronic IHD and sudden cardiac death. However, these syndromes are 
all relatively late manifestations of coronary atherosclerosis. Atherosclerosis, as the 
predominant underlying cause of IHD, begins early in life but manifests only after 
occlusions reach a critical stage (dos Santos et a/., 2008). Acute coronary 
syndrome is applied to three catastrophic manifestations of IHD, namely unstable 
angina, acute myocardial infarction and sudden cardiac death. While ischemia to 
myocardium rapidly (minutes) leads to loss of function and causes necrosis after 
20 to 40 minutes, gross and histological changes of infarction require hours to days 
to develop (Kumar eta/., 2007). 
However, during early IHD events, no symptom is detectable. By the time for onset 
of symptoms, the IHD has by far reached the stage of irreversible injury and 
myocyte death with the predominant pattern of coagulation necrosis. The resulting 
massive myocardial damage and dysfunction are often fatal by ultimate culmination 
of myocardial infarction (Chattopadhyay and Bandyopadhyay, 2006). Currently, the 
diagnosis of myocardial infarction is based on symptoms, electrocardiographic 
changes, and measurement of serum CK-MB and troponins (Panteghini, 2004). If 
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the disease can be detected earlier before necrosis, this can definitely reduce the 
morbidity and mortality rate of IHD. 
Biomarkers provide a new insight to reliably rule out myocardial damage and 
earlier detection of myocardial ischemia both with and without the presence of 
irreversible myocyte injury. The term "biochemical marker" of heart failure is used 
to define a biochemical substance whose plasma (or serum) levels correlate with 
the clinical and hemodynamic status and predict the prognosis of patients with 
heart failure (Apple et a/., 2002). Early diagnosis allows appropriate treatment in 
patients suspected of having IHD and the prevention of adverse outcomes. From 
this perspective, over the last decade, there has been an explosion of information 
generated on the role of inflammation, endothelial dysfunction and of specific 
serum biomarkers in the development of atherosclerosis. A large list of relevant 
cardiac biomarkers has thus been created along with strong evidence that these 
biomarkers act synergistically to increase an individual's risk for experiencing a 
heart attack (Oemrawsingh eta/., 2008). 
Generally, all the potential cardiac biomarker are being classified into two class, 
known as markers of early injury/ischemia as well as markers of inflammation and 
coronary plaque instability and disruption. Among all these potential cardiac 
biomarkers, C-reactive protein (CRP) appeared to have strongest association to 
the predictive risk of future cardiovascular events (Kaperonis et a/., 2006, Rifai and 
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Ridker, 2001) This intriguing finding has provoke numerous epidemiological studies 
and clinical studies on CRP, revealing CRP higher stability and reliability as a 
cardiovascular events predictor when compared with other cardiac biomarkers( de 
Ferranti and Rifai, 2007). 
However, CRP production has been related to part of the nonspecific acute-phase 
response. CRP is elevated to varying degrees in numerous conditions, including 
inflammation, infection, malignancy, tissue damage autoimmune disorder and 
others conditions. Thus, CRP values can never be diagnostic on their own and can 
only be interrelated at the bedside, in full knowledge of all other clinically and 
pathological results (Pepys and Hirschfield, 2003). In particular, markers of plaque 
destabilization and/ or markers of myocardial ischemia can added to the existing 
markers if shown to contribute to the independent information of IHD events. 
Hence, there is always an imperative need for discovering of other potential 
cardiac biomarkers to confront with IHD. 
In this study, CRP is used as a reference to investigate the possibility of human 
choline kinase a (hCK-a) as a novel cardiac biomarker. hCK-a is a metabolic 
enzyme involved in the synthesis of phosphatidylcholine. The roles of hCK-a in cell 
growth, cell stress and defense mechanisms have been extensively investigated. It 
is also found to be overexpressed in a variety of human cancers such as mammary, 
lung, colorectal and prostate adenocarcinomas (Gallego-Ortega et a/., 2006). 
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However, there are no data indicated the relationship of hCK-a with IHD events. 




1. To optimize Enzyme-linked lmmunosorbant Assay (ELISA) methods to measure 
CK-a level in blood. 
2. To compare the CK-a protein level in blood between apparently healthy 
volunteers and IHD patients. 
3. To measure mRNA expression of CK-a in comparison between apparently 
healthy volunteers and IHD patients. 
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3.0 Literature review 
Myocardial ischemia or IHD represents a mismatch in coronary supply and 
myocardial demand. The various clinical symptoms caused by acute myocardial 
ischemia after plaque disruption are referred to as acute coronary syndromes 
(ACS). The fundamental role of atherosclerosis as the causative event on IHD is 
undisputable. Atherosclerosis, comes from Greek root words for "gruel" and 
"hardening" (Kumar et a/., 2007). For the major part of 20th Century, 
atherosclerosis has been known as bland lipid storage disease. Hyperlipidemia or 
more specifically hypercholesterolemia is the dominant theory for antherogenesis. 
Nonetheless, this theory of is seem to be too simplistic. In 1908, Sir William Osler 
first proposed the role of inflammation and infection in the pathogenesis of 
atherosclerosis (Osler, 1908). Since then, numerous studies on the relationship 
between inflammation and atherosclerosis had been done. 
Atherosclerosis is characterized by intima lesions known as atherosclerotic 
plaques that protrude into vascular lumina. An atheromatous plaque consists of a 
raised lesion with soft, yellow core of lipid covered by a firm, white fibrous cap. The 
cellular mechanisms involved in the pathologenesis of IHD are complex and 
involve interaction of a number of cell types. For instances, mononuclear cells, 
macrophages and T -lymphocytes are prominent in atherosclerotic plaques (Navab 
et a/., 1994, Morena et a/., 1994). Besides obstructing the blood flow, 
atherosclerotic plaques can weaken the underlying media and can themselves 
rupture. Inflammation and immune cell activation appears to play a key role in the 
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loss of collagen in the fibrous cap, a prelude to fibrous cap rupture, through release 
of collagen degrading enzymes. Furthermore, inflammation may also play a key 
role in the death of collagen synthesizing smooth muscle cells which further 
contributes to loss of fibrous cap integrity (Kumar eta/., 2007). 
When these atherosclerotic plaques ruptured, they exposure of the plaque core 
activates the clotting cascade and results in thrombosis within the plaque. The 
acute catastrophic vessel thrombosis is then followed by the initiation of platelet 
aggregation (Libby eta/., 2002). 
Three possible mechanisms by which damage to the myocardium may occur are 
discussed by Collison and Gaze (2007). Firstly, intraluminal platelet aggregation 
may cause sufficient vascular occlusion for cardiomyocyte damage to occur. 
Occlusion does not have to be total to produce myonecrosis. Partial occlusion will 
produce a reduction in the rate of blood supply in the myocardium downstream. If 
there is already supply/demand mismatch in this area, the reduction in blood 
supply may be enough to render an area of myocardium non-viable. The tissue will 
then become sufficiently ischemic for necrosis to occur. This is most likely to affect 
small areas of myocardium at the watersheds of different branches of the vascular 
supply. 
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